• Citer

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

par Bajetta, Emilio;Di Leo, Angelo ;Zampino, Maria Julia;Sertoli, Mario Roberto;Comella, G;Barduagni, Mario;Giannotti, Benvenuto;Queirolo, Paola;Tribbia, Giuliana;Bernengo, Maria Grazia Razia;Menichetti, Ettore Tito;Palmeri, Sergio;Russo, Annapina;Cristofolini, Mario;Erbazzi, Anna;Fowst, Camilla;Criscuolo, Domenico;Bufalino, Rosaria;Zilembo, Nicoletta;Cascinelli, Natale
Référence Journal of clinical oncology, 12, 4, page (806-811)
Publication Publié, 1994

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma
Auteur:	Bajetta, Emilio; Di Leo, Angelo; Zampino, Maria Julia; Sertoli, Mario Roberto; Comella, G; Barduagni, Mario; Giannotti, Benvenuto; Queirolo, Paola; Tribbia, Giuliana; Bernengo, Maria Grazia Razia; Menichetti, Ettore Tito; Palmeri, Sergio; Russo, Annapina; Cristofolini, Mario; Erbazzi, Anna; Fowst, Camilla; Criscuolo, Domenico; Bufalino, Rosaria; Zilembo, Nicoletta; Cascinelli, Natale
Informations sur la publication:	Journal of clinical oncology, 12, 4, page (806-811)
Statut de publication:	Publié, 1994
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
	Dacarbazine -- administration & dosage -- adverse effects -- therapeutic use
	Female
	Humans
	Interferon-alpha -- administration & dosage
	Male
	Melanoma -- drug therapy -- secondary
	Middle Aged
	Recombinant Proteins
	Skin Neoplasms -- drug therapy -- pathology
	Survival Analysis
	Treatment Outcome
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:scp/0028218050
	info:pmid/8151323
	VX-005563